UTRECHT, THE NETHERLANDS, Merus BV, a biopharma focusing on antibody therapeutics, has announced a 31 million euro ($42 million US) extension to a Series B financing round, bringing the total raised to 47.6 million euro ($65 million US).
A Dutch biopharmaceutical company focused on human antibody therapies has added an additional 31 million euro ($42 million US) to its Series B financing round, bringing the total raised to 47.6 million euro ($65 million US.)
Merus BV, based in Utrecht, The Netherlands, added money from new investor Johnson and Johnson Development Corporation, along with funds from existing investors Novartis Venture Fund, Pfizer Venture Investments, Bay City Capital, LSP (Life Sciences Partners), and Aglaia Oncology Fund.
Merus will use the new funds to broaden its portfolio of pre-clinical programs for the treatment of cancer patients and to bring its lead programs into phase I clinical testing.
The investment of JJDC in Merus B.V. was announced at the launch of the Johnson & Johnson Innovation Centre in London.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
